4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Women's Health by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1727 ongoing clinical trials involving Women's Health
Of the 1727 trials,673 trials are in Phase II
Furthermore, 876 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Women's Health by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Women’s Health. The largest number of ongoing clinical trials for Women’s Health is conducted in the Asia-Pacific region. North America, Europe and Middle East and Africa are among some of the other prominent regions engaged in Women’s Health-related drug trials.

Ain Shams University : The leading ongoing Women’s Health related clinical trial sponsor

Ain Shams University is the top sponsor for Women’s Health-related ongoing clinical trials.

Cairo University, Assiut University, Tehran University of Medical Sciences and Women's Hospital School of Medicine Zhejiang University are among other notable clinical trial sponsors involved in Women’s Health. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Women’s Health

Human papillomavirus types L1 proteins 6, 11, 16, and 18 (Gardasil / Silgard), Levonorgestrel (Jaydess/ Luadei/ Levonelle/ Microlut/ Jadelle/ Jaden/ 28 mini) and Somatropin (Norditropin, Norditropin Simplexx, Norditropin Flexpro, Norditropin Penset/, Nanormon, Norditropin Nordilet, Norditropin Nordiflex, Norditropin S) are among the key marketed drugs involving Women’s Health.

Human papillomavirus types L1 proteins 6, 11, 16, and 18 is an adjuvant non-infectious recombinant quadrivalent vaccine acts as immunizing preparation against human papillomavirus. Human papillomavirus types L1 proteins 6, 11, 16, and 18 is formulated as suspension for injection administered by intramuscular route. Human papillomavirus types L1 proteins 6, 11, 16, and 18 was first approved in 2006 and is marketed globally in the US, UK, Russia, Japan, France and Germany by several prominent pharma giants including Merck & Co Inc.

Levonorgestrel is a synthetic progestin that acts as a contraceptive agent. It functions via Progesterone Receptor Agonist mechanism of action. Levonorgestrel is formulated as inserter or implant for intrauterine route and tablets, coated tablets, film coated tablets and sugar coated tablets for oral route of administration. Levonorgestrel was first approved in 1973 and is marketed globally in the US, UK, Australia, Canada, France and Germany by several prominent pharma giants including Bayer Healthcare LLC.

Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on Therapy Areas to inform business strategy and pinpoint opportunities and risks. Visit Report Store